<DOC>
	<DOCNO>NCT00169832</DOCNO>
	<brief_summary>HYPOTHESES - Rosiglitazone diabetic patient previous coronary bypass surgery may prevent slow progression atherosclerosis SVGs native coronary artery . - Rosiglitazone favorable effect adipose tissue distribution variable well thrombosis , pro-inflammatory , lipid profile diabetic patient coronary bypass artery surgery . - Rosiglitazone therapy influence favorably metabolism clinical outcome diabetic patient coronary artery bypass surgery . OBJECTIVES - PRIMARY To assess efficacy rosiglitazone reduce atherosclerosis progression vein graft diabetic patient coronary bypass surgery use IVUS image 12 mo follow-up . - SECONDARY - To prospectively compare secondary IVUS endpoint . - To prospectively compare angiographic endpoint . - To prospectively compare metabolic risk factor endpoint . - To prospectively compare body composition distribution endpoint . - To prospectively compare clinical outcome rosiglitazone versus standard care use composite endpoint .</brief_summary>
	<brief_title>Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery : The VICTORY Trial</brief_title>
	<detailed_description>STUDY DESIGN This prospective multicenter randomize placebo-controlled double-blind trial assess efficacy safety rosiglitazone prevention atherosclerosis progression vein graft native coronary artery diabetic patient . Stable diabetic patient previous coronary bypass surgery ( ≥ 1 year ≤ 10 year ) screen . After baseline evaluation , eligible patient undergo baseline coronary angiogram . IVUS perform segment length least 40 mm SVG suitable IVUS analysis segment length least 20 mm anastomose native coronary artery correspond SVG chosen . Following IVUS procedure , patient randomize either rosiglitazone treatment placebo addition standard clinical care . Study drug titrate 8-week period dose 8 mg/day ( maximum tolerate dose ) . The patient receive study drug placebo 50-54 week double-blind manner . At begin 2 , 4 , 6 , 8 , 10 12 month treatment , patient subject set morphological , physiological metabolic evaluation . At final visit ( 12 month ) , patient also submit IVUS angiography .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>AT SCREENING : 1 . Male female , age ≥ 40 year &amp; ≤ 75 year . 2 . Women childbearing potential contraceptive measure , nonchildbearing potential surgically sterile . 3 . Type 2 diabetes mellitus . 4 . Patients new medication hyperglycemia change dose oral hypoglycemic medication within last 3 mo prior screen . 5 . Diabetic patient ischemic heart disease CABG least one SVG ( ≥1 yr &amp; ≤10 yr ) . 6 . Patient agree participate . 7 . Patient legally capable give consent understand participation study entail , potential risk benefit , freedom withdraw without prejudice subsequent medical arrangement treatment , sign ICF prior protocol specific procedure . AT IVUS &amp; ANGIOGRAPHY ( VISIT 2 ) : Subject eligible least 1 ) , 2 ) 3 ) follow criterion apply : 1 . Patient least 1 patent SVG . 2 . Segment length least 40 mm SVG suitable IVUS . 3 . Reference target ( SVG ) diameter ≥ 2.5 mm . If anastomose native coronary artery non graft coronary artery evaluate , follow criterion must meet : 4 . Reference target anastomose native coronary artery non graft coronary artery diameter≥ 2.5 mm . 5 . Segment length least 20 mm anastomose native coronary artery correspond SVG chosen , case impossibility perform IVUS anastomose coronary artery , non graft coronary artery ( ≥ 30 mm length segment ) might use reference . AT SCREENING : 1 . Clinically significant abnormality screen test &amp; exam . 2 . Type 1 diabetes history diabetic ketoacidosis . 3 . Uncontrolled type 2 diabetes mellitus . 4 . Recent MI ACS ( ≤ 90 day ) . 5 . History hypersensitivity thiazolidinediones ( TZD ) compound similar chemical structure . 6 . Last LVEF≤ 35 % . 7 . SBP &gt; 170mmHg DBP &gt; 100mmHg screening/baseline appropriately treat control prior randomization . 8 . Unstable Canadian Cardiovascular Society class III IV angina , acute heart failure congestive heart failure ( NYHA class III IV ) . 9 . History hepatocellular reaction/severe oedema/other potentially fluidrelated AE associate use TZD PPARγ agonist . 10 . Hepatic disease . 11 . Renal dysfunction . 12 . Anemia . 13 . TG ≥ 10 mmol/L . 14 . History PCI SVG ( ) . 15 . Known occlusion ( ) SVG ( ) . 16 . Treatment involve TZD within 3 mo prior screen . 17 . Chronic use ( ≥ 6 mo ) insulin glycemic control time past administration insulin time within last 12 mo . 18 . Allergy contrast agent . 19 . Current intake anorectic agent take anorectic agent equivalent within 3 mo prior screen . 20 . Patients oral injectable corticosteroid use regular recurrent basis . 21 . Recent history/suspicion current drug abuse alcohol abuse within last 6 mo . 22 . Women breast feeding , pregnant , plan become pregnant conduct trial 30 day study completion . 23 . Other illness precludes survival . 24 . History malignancy within last 5 yr . 25 . Concurrent participation investigational device drug study and/or receive experimental therapeutic agent within 30 day screen . 26 . Use investigational drug glycemic control within 3 mo screening . 27 . Patient travel town/country period exceed 2 mo . 28 . Medical condition may interfere intake and/or absorption study medication . 29 . Patients unwilling unable comply procedure . 30 . Recent major surgery within 90 day screen . AT IVUS AND ANGIOGRAPHY ( VISIT 2 ) : 1 . PCI perform target segment ( ) CABG . 2 . Target SVG and/or target native coronary artery show ≥ 50 % angiographic lesion preclude IVUS . 3 . Thrombus/thrombus aspect target vessel . 4 . Target vessel subjected surgical endarterectomy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Atherosclerosis progression</keyword>
	<keyword>Ischemic heart disease</keyword>
	<keyword>Saphenous vein graft</keyword>
	<keyword>Metabolic risk factor</keyword>
	<keyword>Rosiglitazone</keyword>
</DOC>